GlassScriptPhysician profile
Ibitoro Osakwe
NPI 1245338474
$573.44
in general payments reported to CMS, 2019-2025
16 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $132 · 2024: $245 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.61 | 2024-2025 | Tepezza |
| Abbott Laboratories | $66.45 | 2023-2024 | Freestyle Libre 3 |
| Mannkind Corporation | $63.44 | 2025 | |
| Horizon Therapeutics Plc | $41.90 | 2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $37.39 | 2023-2024 | |
| Novo Nordisk INC | $37.02 | 2025 | Ozempic |
| Radius Health, INC. | $29.60 | 2023 | Tymlos |
| Cequr Corporation | $29.19 | 2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $25.48 | 2025 | Yorvipath |
| Corcept Therapeutics | $25.43 | 2024 | Korlym |
| Arkray USA, INC. | $24.50 | 2024 | |
| Eisai INC. | $23.72 | 2024 | |
| Lilly USA, LLC | $18.78 | 2023 | Jardiance |
| Amphastar Pharmaceuticals, INC. | $17.57 | 2024 | Baqsimi |
| Recordati_rare_diseases_inc. | $16.90 | 2024 | Isturisa, Signifor Lar |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $15.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibitoro Osakwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.